VANDA PHARMS INC
Bysanti
bipolar I disorder and schizophrenia
Resolved
137days ago
Approval decision · Feb 20, 2026
What's at stake
A final FDA approval decision on Bysanti for bipolar I disorder and schizophrenia is expected Feb 20, 2026.
Primary source
· SEC 8-K
verified 14h ago
“BYSANTI TM (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia on February 20, 2026.”